Fig. 3.

Overexpression of HER2 leads to tamoxifen resistance in T47D cells. a T47D cells were transfected with HER2-pEGFP-N1 plasmid (OE-HER2) or pEGFP-N1 vector as a control (Vector). Immunoblot analysis was performed using the indicated antibodies. b T47D cells were transfected with the HER2 overexpression vector for 48 h, and immunoprecipitation and immunoblot analysis were performed with the indicated antibodies. c MTT assays in HER2-overexpressing T47D cells treated with 17β-E2 and/or tamoxifen. T47D cells were transfected with pEGFP-N1 vector or HER2-pEGFP-N1 (OE-HER2) for 24 h, and then treated with vehicle (CON), 17β-E2 (E2) (10 nmol/L), tamoxifen (TAM) (1 μmol/L) or combination treatment (E2/TAM) for another 48 h. MTT assays were then performed. *P < 0.05